AbCellera Biologics, Inc. (ABCL)
| Market Cap | 7.88B |
| Revenue (ttm) | 233.16M |
| Net Income (ttm) | 118.92M |
| Shares Out | 269.50M |
| EPS (ttm) | 0.45 |
| PE Ratio | 64.96 |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | April 22 |
| Last Price | $29.23 |
| Previous Close | $29.06 |
| Change ($) | 0.17 |
| Change (%) | 0.58% |
| Day's Open | 29.50 |
| Day's Range | 28.26 - 29.98 |
| Day's Volume | 419,310 |
| 52-Week Range | 23.20 - 71.91 |
VANCOUVER, British Columbia & SAN DIEGO--(BUSINESS WIRE)---- $ABCL--AbCellera and Empirico Announce Strategic Multi-Target Antibody Discovery Collaboration
VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera to Present Virtually at Upcoming Investor Conferences
VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL #COVID19--Published data show high potency of bamlanivimab against SARS-CoV-2 and support its clinical effectiveness to treat and prevent COVID-19.
AbCellera Biologics Inc (NASDAQ: ABCL) has announced agreements to expand its collaboration with Gilead Sciences Inc (NASDAQ: GILD), including a multi-year, multi-target antibody discovery collaboration...
AbCellera and Gilead Sciences Announce New Multi-Year, Multi-Target Antibody Discovery Collaboration
VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera and Gilead Sciences Announce New Multi-Year, Multi-Target Antibody Discovery Collaboration
VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera Reports Full Year 2020 Business Results
VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL #COVID19--AbCellera-Discovered Bamlanivimab Together with Etesevimab Reduced Hospitalization and Prevented Death in Phase 3 Trial for Early COVID-19
VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL #COVID19--EMA Advises Use of AbCellera-Discovered Bamlanivimab, Alone or Together with Etesevimab, to Treat Confirmed COVID-19 Patients
VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera will present at the 10th Annual SVB Leerink Global Healthcare Conference on Thursday, February 25, 2021 at 1:20 p.m. Pacific Time.
VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera announced today that Ester Falconer, Ph.D., has been appointed Chief Technology Officer, effective January 28, 2021.
IPO stock AbCellera Biologics shattered records in June when it began testing of an antibody-based Covid-19 treatment in just 90 days. Now it shows signs of making waves in the market The post How IPO S...
Usana Health Sciences (NYSE: USNA) shares are trading higher after the company reported better-than-expected Q4 EPS and sales results and issued fiscal year 2021 EPS and sales guidance above estimates. ...
VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL #EUA--AbCellera-Discovered Antibody, Bamlanivimab, Administered with Etesevimab Receives FDA Emergency Use Authorization for COVID-19
VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera will announce its fourth-quarter and full-year 2020 financial results and hold an earnings conference call on Monday, March 29, 2021.
VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL #COVID19--AbCellera-Discovered Antibody, Bamlanivimab, to be Developed with VIR-7831 for the Treatment of COVID-19
VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL #COVID19--AbCellera-Discovered Antibody, Bamlanivimab, Administered with Etesevimab Reduced Risk of COVID-19 Hospitalizations and Death by 70%
VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL #COVID19--Bamlanivimab (LY-CoV555) significantly reduced the risk of contracting symptomatic COVID-19 among residents and staff of long-term care f...
VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera (Nasdaq: ABCL) today announced it has expanded its intellectual property (IP) portfolio to include its Trianni Mouse® technology.
AbCellera CEO on effectiveness of Covid-19 anitbody treatment
AbCellera Biologics CEO Carl Hansen joins 'Closing Bell' to discuss the company's partnership with Eli Lilly in developing monoclonal antibody treatment and the company's Covid-19 treatments.
Andreas Halvorsen (Trades, Portfolio) has revealed two new buys in 4D Molecular Therapeutics Inc. (NASDAQ:FDMT) and AbCellera Biologics Inc. (NASDAQ:ABCL), according to GuruFocus' Real-Time Picks, a Pre...
VANCOUVER, British Columbia--(BUSINESS WIRE)--AbCellera-Discovered Neutralizing Antibody for COVID-19 Enters New Pragmatic Study in New Mexico
VANCOUVER, British Columbia--(BUSINESS WIRE)--AbCellera Announces Closing of Initial Public Offering and Exercise in Full of the Underwriters' Option to Purchase Additional Shares
Hot initial public offerings aren't just for technology companies.
Four companies increased the size of their deals.
VANCOUVER, British Columbia--(BUSINESS WIRE)--AbCellera announced the pricing of its initial public offering of 24,150,000 common shares at a price to the public of $20.00 per share.
AbCellera is continuing forward with its IPO plans and has provided new details in a filing with the SEC that investors will want to know. The post ABCL Stock IPO: When Does AbCellera Go Public?
AbCellera Biologics has filed to raise $357 million in an IPO. The firm provides an antibody research platform to biopharmaceutical firms worldwide.
AbCellera Biologics Inc. ABCL, said Monday that terms of its initial public offering have been set, which could value the artificial intelligence (AI)-powered drug discovery company at up to $4.52 billion.
AbCellera-Discovered Antibody Granted Interim Authorization by Health Canada as a Treatment for COVID-19.
Peter Thiel-backed biotech developer AbCellera Biologics Inc, which has partnered with Eli Lilly for its COVID-19 antibody drug, on Friday filed for an initial public offering on the Nasdaq.
AbCellera Biologics, which provides an AI powered drug discovery platform for antibody therapies, filed on Friday with the SEC to raise up to $200 million in an initial public offering.
AbCellera Biologics, Inc. has filed to go public with an IPO on the NASDAQ.
About ABCL
AbCellera's full-stack, artificial intelligence-, or AI, powered drug discovery platform searches and analyzes the database of natural immune systems to find antibodies that can be developed as drugs. We believe our technology increases the speed and the probability of success of therapeutic antibody discovery, including enabling discovery against targets that may otherwise be intractable. Rather than advancing our own clinical pipeline of drug candidates, we forge partnerships with drug developers of all sizes, from large cap pharmaceutical to... [Read more...]
| Industry Biotechnology | IPO Date Dec 11, 2020 |
| CEO Carl L. G. Hansen | Employees 206 |
| Stock Exchange NASDAQ | Ticker Symbol ABCL |
Analyst Forecasts
The average 12-month stock price forecast for ABCL is 52.20, which is an increase of 78.58% from the latest price.